THE SIDE EFFECTS OF SORAFENIB, SUNITINIB, AND TEMSIROLIMUS AND THEIR THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA

by N. Bhojani, C. Jeldres, J.-J. Patard, P. Perrotte, N. Suardi, G. Hutterer, F. Patenaude, S. Oudard, P. I. Karakiewicz
Published 2014-08-01

THE SIDE EFFECTS OF SORAFENIB, SUNITINIB, AND TEMSIROLIMUS AND THEIR THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA

by N. Bhojani, C. Jeldres, J.-J. Patard, P. Perrotte, N. Suardi, G. Hutterer, F. Patenaude, S. Oudard, P. I. Karakiewicz
Published 2014-08-01

The effect of age on cancer-specific mortality in patients with prostate cancer: A population-based study across all stages

by S. Knipper, A. Pecoraro, C. Palumbo, G. Rosiello, S. Luzzago, M. Deuker, Z. Tian, S.F. Shariat, F. Saad, D. Tilki, M. Graefen, P.I. Karakiewicz
Published 2020-07-01

Comparison between small renal masses 0–2cm vs. 2.1–4 cm in size: a population-based study

by A. Pecoraro, M. Deuker, G. Rosiello, F. Stolzenbach, S. Luzzago, Z. Tian, S.F. Shariat, F. Saad, A. Briganti, C. Fiori, F. Porpiglia, P.I. Karakiewicz
Published 2020-10-01

State-of-the-art weakly supervised automated classification of prostate cancer tissue microarrays via deep learning: Can sufficient accuracy be achieved without manual patch level...

by S-R. Leyh-Bannurah, U. Wolffgang, J. Schmitz, V. Ouellet, F. Azzi, Z. Tian, B. Helmke, M. Graefen, L. Budäus, P.I. Karakiewicz, D. Trudel, F. Saad
Published 2020-07-01

Synchronous metastases rates in T1 renal cell carcinoma: A SEER-based study

by A. Pecoraro, C. Palumbo, S. Knipper, F.A. Mistretta, G. Rosiello, Z. Tian, F.S. Sharok, L. Lavallée, F. Saad, A. Briganti, C. Fiori, F. Porpiglia, P.I. Karakiewicz
Published 2020-07-01

Distribution of histological subtypes and tumor grade according to tumor size in T1-T2 surgically treated renal cell carcinoma

by A. Pecoraro, G. Rosiello, C. Palumbo, S. Knipper, S. Luzzago, M. Deuker, F. Stolzenbach, Z. Tian, S.F. Shariat, F. Saad, A. Briganti, C. Fiori, F. Porpiglia, P.I. Karakiewicz
Published 2020-07-01

Prognostic differences in patients with T1a renal cell carcinoma according to clinical size

by P.I. Karakiewicz, G. Rosiello, A. Pecoraro, M. Deuker, L.F. Stolzenbach, Z. Tian, A. Larcher, F. Montorsi, S.F. Shariat, A. Kapoor, F. Saad, A. Briganti, U. Capitanio
Published 2020-10-01

The clinical value of the urokinase-plasminogen activator system (uPA) in patients with radical cystectomy (RC) for bladder cancer

by F. Janisch, D. D’Andrea, T. Iwata, S. Kimura, M. Abufaraj, D. Enikeev, P.V. Glybochko, P.I. Karakiewicz, P. Nyiradi, H. Fajokvic, A. Haitel, V. Seebacher, M. Rink, S.F. Shariat
Published 2020-07-01

Pre-operative risk calculator of the probability of completing nephron-sparing surgery for kidney cancer: The key role of surgical experience and approach

by G. Colandrea, A. Larcher, G. Rosiello, F. Muttin, G. Baiamonte, C. Re, P. Rigatti, G. Guazzoni, P.I. Karakiewicz, A. Mottrie, F. Dehò, A. Briganti, A. Salonia, F. Montorsi, R. Bertini, U. Capitanio
Published 2020-10-01

Higher cancer mortality in rural upper urinary tract urothelial carcinoma patients

by C.Collà Ruvolo, L.N. Nocera, G. Califano, R. La Rocca, G. Spena, M. Creta, M. Capece, G. Celentano, F. Crocetto, F. Mangiapia, P. Verze, F. Fusco, A. Palmieri, N. Longo, C. Imbimbo, A. Brigamti, V. Mirone, P.I. Karakiewicz
Published 2020-10-01

Focal therapy for prostate cancer: do apical lesions correlate with worse outcomes?

by A. Stabile, G. Gandaglia, N. Fossati, S. Scuderi, F. Barletta, L. Nocera, R. Leni, D. Robesti, E. Mazzone, G. Rosiello, M. Bandini, C.A. Bravi, N. Suardi, M. Moschini, P.I. Karakiewicz, P. Macek, N. Cathala, X. Cathelineau, A. Briganti, F. Montorsi, R.Sanchez Salas
Published 2020-10-01

Radical prostatectomy versus radiotherapy in M1a and low volume M1b prostate cancer patients: an indirect comparison with the STAMPEDE trial arm H

by G. Gandaglia, A. Heidenreich, D. Pfister, S. Shariat, B. Grubmuller, G. Motterle, G. Devos, D. Robesti, F. Scalvi, G. Fallara, A. Pellegrino, C. Berghen, W. Everaerts, N. Fossati, S. Scuderi, A. Martini, P.I. Karakiewicz, F. Montorsi, S. Joniau, R. Karnes, F. Barletta, C.A. Bravi, A. Briganti
Published 2020-10-01

Age and Gleason score upgrading between prostate biopsy and radical prostatectomy. Is this still true in the mp-MRI era?

by F. Pellegrino, A. Stabile, R.J. Karnes, G. Motterle, N. Fossati, G. Gandaglia, F. Barletta, S. Scuderi, V. Cucchiara, D. Robesti, A. Rizzo, E. Mazzone, G. Rosiello, C.A. Bravi, R. Leni, M. Moschini, G. Brembilla, A. Esposito, P.I. Karakiewicz, F. Montorsi, F. De Cobelli, A. Briganti
Published 2020-10-01

The relative drop of PSA values after androgen deprivation therapy is a useful parameter to select the best candidate for cytoreductive radical prostatectomy among patients with ol...

by E. Mazzone, A. Heidenreich, G. Gandaglia, D. Pfister, S. Shariat, B. Grubmuller, N. Fossati, A. Stabile, S. Scuderi, F. Pellegrino, G. Sorce, G. Fallara, G. Rosiello, A. Martini, M. Bandini, V. Cucchiara, E. Zito, A. Pellegrino, P.I. Karakiewicz, M. Moschini, R.J. Karnes, F. Montorsi, A. Briganti
Published 2020-10-01

Should we target all visible areas at mp-MRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series

by A. Stabile, R.J. Karnes, G. Motterle, N. Fossati, G. Gandaglia, F. Barletta, S. Scuderi, V. Cucchiara, L. Nocera, E. Zaffuto, F. Scalvi, D. Robesti, D. Cannoletta, E. Zito, M. Menean, E. Mazzone, P. Dell’Oglio, A. Salonia, P.I. Karakiewicz, F. Montorsi, F. De Cobelli, A. Briganti
Published 2020-07-01

The impact of persistently elevated PSA levels on progression and survival of patients undergoing cytoreductive radical prostatectomy for oligometastatic prostate cancer

by D. Cannoletta, G. Gandaglia, D. Pfister, S. Shariat, B. Grubmuller, N. Fossati, A. Stabile, S. Scuderi, F. Pellegrino, G. Sorce, G. Fallara, A. Martini, V. Cucchiara, D. Robesti, A. Rizzo, F. Scalvi, A. Gallina, E. Mazzone, P.I. Karakiewicz, R.J. Karnes, F. Montorsi, A. Briganti, A. Heidenreich
Published 2020-10-01

A positive PSMA PET/CT Predicts more aggressive disease progression in patients with biochemical recurrence after radical prostatectomy

by L. Nocera, G. Gandaglia, N. Fossati, V. Cucchiara, D. Robesti, F. Barletta, S. Scuderi, A. Rizzo, E. Zito, A. Gallina, E. Camisassa, L. Sciacqua, M. Droghetti, G. Sorce, F. Pellegrino, E. Mazzone, A. Stabile, C.A. Bravi, A. Martini, P.I. Karakiewicz, M. Moschini, F. Montorsi, A. Briganti
Published 2020-10-01

Initial negative multi-parametric MRI with concomitant negative biopsy: Are true negative findings confirmed over time? Results from a single institution series

by A. Stabile, N. Fossati, E. Zaffuto, G. Gandaglia, D. Robesti, D. Cannoletta, M. Menean, E. Mazzone, S. Comana, V. Cucchiara, G. Fallara, V. Cucchiara, P. Dell’oglio, A. Martini, M. Moschini, A. Rizzo, V. Mirone, A. Necchi, A. Salonia, P.I. Karakiewicz, F. Montorsi, F. De Cobelli, A. Briganti
Published 2020-07-01

External validation of the 2019 Briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection

by G. Gandaglia, A. Martini, G. Ploussard, N. Fossati, N. Suardi, A. Stabile, F. Dehò, M. Droghetti, P.I. Karakiewicz, P. De Visschere, H. Borgmann, I. Heidegger, A. Kretschmer, R. Mathieu, C. Surcel, D. Tilki, I. Tsaur, M. Valerio, R. Van Den Bergh, P. Ost, F. Montorsi, A. Briganti
Published 2020-07-01